胰岛素治疗的2型糖尿病中HbA1c之外的血糖调控:DIALECT-2队列的真实世界证据
研究纳入DIALECT-2队列中79例胰岛素治疗的2型糖尿病患者,按HbA1c分为低、中、高三组,用FreeStyle Libre连续血糖监测比较血糖参数。结果显示高HbA1c组并未减少夜间低血糖发生,低HbA1c组也未达到最高TIR,提示需用CGM参数个体化优化血糖管理。
要点
- 高HbA1c患者夜间低血糖并未减少,低HbA1c者TIR并非最高。
- 所有患者夜间低血糖发作频率和持续时间均高于白天。
- HbA1c分组中低与中组TIR无差异,但低组TBR更高、TAR更低。
核心结论
- 高HbA1c并未减少夜间低血糖发生,低HbA1c与最高TIR无关。
- 优化个体化血糖控制需使用CGM衍生参数等新工具。
研究设计与样本
- DIALECT-2队列研究,纳入79例胰岛素治疗的2型糖尿病患者。
- 按HbA1c分为低(≤53 mmol/mol或≤7%)、中(54-62 mmol/mol或7.1-7.8%)、高(≥63 mmol/mol或≥7.9%)三组。
- 用FreeStyle Libre传感器行CGM,中位监测10(7-12)天/患者。
主要发现
- 低与中HbA1c组TIR无差异:76.8% [68.3-88.2] vs. 76.0% [72.5-80.1]。
- 低HbA1c组TBR更高、TAR更低:7.7% [2.4-19.1] vs. 0.7% [0.3-6.1]和8.2% [5.7-17.6] vs. 20.4% [11.6-27.0],P < 0.05。
- 最高HbA1c组TIR更低(52.7% [40.9-67.3])、TAR更高(44.1% [27.8-57.0]),P < 0.05,但夜间TBR未减少。
- 所有患者夜间TBR发作更多(0.06 ± 0.06/h vs. 0.03 ± 0.03/h;P = 0.002)且更长(88.0 [45.0-195.5] vs. 53.4 [34.4-82.8]分钟;P < 0.001)。
临床怎么用
- 胰岛素治疗的2型糖尿病患者应结合CGM参数评估血糖,而非仅用HbA1c。
- 关注夜间低血糖风险,即使HbA1c较高也应警惕。
局限性
- 样本量较小(n = 79)。
- CGM监测时长中位仅10天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate glucose variations associated with glycated hemoglobin (HbA1c) in insulin-treated patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients included in Diabetes and Lifestyle Cohort Twente (DIALECT)-2 (n = 79) were grouped into three HbA1c categories: low, intermediate, and high (≤53, 54-62, and ≥63 mmol/mol or ≤7, 7.1-7.8, and ≥7.9%, respectively). Blood glucose time in range (TIR), time below range (TBR), time above range (TAR), glucose variability parameters, day and night duration, and frequency of TBR and TAR episodes were determined by continuous glucose monitoring (CGM) using the FreeStyle Libre sensor and compared between HbA1c categories. RESULTS: CGM was performed for a median (interquartile range) of 10 (7-12) days/patient. TIR was not different for low and intermediate HbA1c categories (76.8% [68.3-88.2] vs. 76.0% [72.5.0-80.1]), whereas in the low category, TBR was higher and TAR lower (7.7% [2.4-19.1] vs. 0.7% [0.3-6.1] and 8.2% [5.7-17.6] vs. 20.4% [11.6-27.0], respectively; P < 0.05). Patients in the highest HbA1c category had lower TIR (52.7% [40.9-67.3]) and higher TAR (44.1% [27.8-57.0]) than the other HbA1c categories (P < 0.05), but did not have less TBR during the night. All patients had more (0.06 ± 0.06/h vs. 0.03 ± 0.03/h; P = 0.002) and longer (88.0 [45.0-195.5] vs. 53.4 [34.4-82.8] minutes; P < 0.001) TBR episodes during the night than during the day. CONCLUSIONS: In this study, a high HbA1c did not reduce the occurrence of nocturnal hypoglycemia, and low HbA1c was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters.
引用
- den Braber N, Vollenbroek-Hutten MMR, Westerik KM, et al. Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort. Diabetes Care. 2021. PMID: 34301732. doi:10.2337/dc20-2241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。